JP2021508318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021508318A5 JP2021508318A5 JP2020531663A JP2020531663A JP2021508318A5 JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5 JP 2020531663 A JP2020531663 A JP 2020531663A JP 2020531663 A JP2020531663 A JP 2020531663A JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- heteroaryl
- heterocycloalkyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims 30
- 150000002367 halogens Chemical class 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- -1 or -NH 2. and Chemical group 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000006692 (C2-C8) heterocyclyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595530P | 2017-12-06 | 2017-12-06 | |
| US62/595,530 | 2017-12-06 | ||
| PCT/US2018/064114 WO2019113242A1 (en) | 2017-12-06 | 2018-12-05 | Tubulin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021508318A JP2021508318A (ja) | 2021-03-04 |
| JP2021508318A5 true JP2021508318A5 (enExample) | 2022-01-11 |
| JP7319977B2 JP7319977B2 (ja) | 2023-08-02 |
Family
ID=66658388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531663A Active JP7319977B2 (ja) | 2017-12-06 | 2018-12-05 | チューブリン阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11040945B2 (enExample) |
| EP (1) | EP3720436A4 (enExample) |
| JP (1) | JP7319977B2 (enExample) |
| KR (1) | KR20200104873A (enExample) |
| CN (1) | CN111727042A (enExample) |
| AU (1) | AU2018380132B2 (enExample) |
| TW (1) | TWI828644B (enExample) |
| WO (1) | WO2019113242A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019200683B2 (en) * | 2018-02-01 | 2024-05-30 | The University Of Sydney | Anti-cancer compounds |
| US11472774B2 (en) | 2018-02-01 | 2022-10-18 | The University Of Sydney | Anti-cancer compounds |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| AU2020319879A1 (en) * | 2019-07-31 | 2022-02-03 | Aclaris Therapeutics, Inc. | Deuterated MK2 pathway inhibitors and methods of using the same |
| US20210147441A1 (en) * | 2019-09-26 | 2021-05-20 | Agency For Science, Technology And Research (A*Star) | Therapeutic compounds and methods of use thereof |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| CN115666566A (zh) | 2020-03-27 | 2023-01-31 | 阿克拉瑞斯治疗股份有限公司 | 用于免疫病况的治疗的mk2途径抑制剂的口服组合物 |
| KR102844239B1 (ko) * | 2020-11-10 | 2025-08-08 | 가천대학교 산학협력단 | 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| IL306101A (en) * | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2205732A1 (de) | 1972-02-08 | 1973-08-16 | Thomae Gmbh Dr K | Neue 4-(4-biphenylyl)-butensaeurederivate |
| IT1044222B (it) * | 1972-05-23 | 1980-03-20 | Zambeletti Spa L | Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata |
| AT336594B (de) | 1973-08-14 | 1977-05-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden |
| US5196543A (en) | 1989-10-17 | 1993-03-23 | Delalande S.A. | 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy |
| CA2083048A1 (en) | 1990-06-14 | 1991-12-15 | James K. Bashkin | Rna hydrolysis/cleavage |
| JP2969618B2 (ja) * | 1995-06-27 | 1999-11-02 | 田辺製薬株式会社 | ピリダジノン誘導体及びその製法 |
| US5756507A (en) | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JP3060454B2 (ja) * | 1996-12-26 | 2000-07-10 | 田辺製薬株式会社 | 医薬組成物 |
| US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| JP4772690B2 (ja) * | 2003-12-03 | 2011-09-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | チューブリン阻害剤 |
| PE20060241A1 (es) | 2004-05-18 | 2006-04-01 | Schering Corp | 2-quinolil-oxazoles sustituidos como inhibidores de pde4 |
| WO2006060108A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| NZ560267A (en) * | 2005-03-15 | 2010-03-26 | 4Sc Ag | N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| US20070254913A1 (en) | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| JP2009185010A (ja) | 2008-02-08 | 2009-08-20 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害剤を含有する医薬 |
| FR2933700B1 (fr) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| CN102470127A (zh) | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
| FR2952934B1 (fr) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| CN102834380B (zh) * | 2010-03-10 | 2015-04-01 | 阿斯利康公司 | 蛋白激酶的抑制剂 |
| RU2576662C2 (ru) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| EP2729146B1 (en) | 2011-07-08 | 2017-03-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
| US20130267712A1 (en) | 2012-04-02 | 2013-10-10 | Board Of Trustees Of Northern Illinois University | Aromatic ketone synthesis with amide reagents and related reactions |
| CN105473559B (zh) | 2013-03-15 | 2019-05-10 | 南洋理工大学 | 用于化学转化的羰基β-碳的活化 |
| AR098475A1 (es) | 2013-11-26 | 2016-06-01 | Bayer Cropscience Ag | Compuestos pesticidas y usos |
| WO2016067009A1 (en) | 2014-10-28 | 2016-05-06 | Redx Pharma Plc | Compounds with activity against bacteria and mycobacteria |
| WO2016119017A1 (en) | 2015-01-30 | 2016-08-04 | The University Of Sydney | Anti-cancer compounds |
| EP3302448B1 (en) | 2015-06-04 | 2023-10-25 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
-
2018
- 2018-12-05 KR KR1020207019403A patent/KR20200104873A/ko not_active Ceased
- 2018-12-05 CN CN201880088716.8A patent/CN111727042A/zh active Pending
- 2018-12-05 US US16/211,051 patent/US11040945B2/en active Active
- 2018-12-05 AU AU2018380132A patent/AU2018380132B2/en active Active
- 2018-12-05 WO PCT/US2018/064114 patent/WO2019113242A1/en not_active Ceased
- 2018-12-05 TW TW107143753A patent/TWI828644B/zh active
- 2018-12-05 EP EP18887114.9A patent/EP3720436A4/en not_active Withdrawn
- 2018-12-05 JP JP2020531663A patent/JP7319977B2/ja active Active
-
2021
- 2021-04-29 US US17/244,767 patent/US12247010B2/en active Active
-
2025
- 2025-02-17 US US19/054,952 patent/US20250188035A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021508318A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2017511357A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| JP2018504437A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2011132222A5 (enExample) | ||
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение |